Orion Corporation: Managers’ transactions – Henrik Stenqvist
ORION CORPORATION
MANAGERS’ TRANSACTIONS
4 MAY 2026 at 16.00 EEST
Orion Corporation: Managers’ transactions – Henrik Stenqvist
Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.
Orion Oyj - Managers' Transactions
____________________________________________
Person subject to the notification requirement
Name: Henrik Stenqvist
Position: Member of the Board/Deputy member
Issuer: Orion Oyj
LEI: 74370029VAHCXDR7B745
Notification type: INITIAL NOTIFICATION
Reference number: 154802/4/4
____________________________________________
Transaction date: 2026-04-30
Venue: OFF-EXCHANGE LIIKETOIMET (XOFF)
Instrument type: SHARE
ISIN: FI0009014377
Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVE
Transaction details
(1): Volume: 436 Unit price: 0 EUR
Aggregated transactions (1):
Volume: 436 Volume weighted average price: 0 EUR
Orion Corporation
| Liisa Hurme President and CEO | Mikko Kemppainen General Counsel |
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orionpharma.com
Orion Pharma is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals as well as active pharmaceutical ingredients, combining our trusted expertise with continuous innovation. We have an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by us are used to treat cancer, respiratory diseases and neurological diseases, among others. In 2025 our net sales amounted to EUR 1,890 million, and we employ about 4,000 professionals worldwide, dedicated to building well-being.
